Sugi Predict

Sugi Predict / Compounds / SCHEMBL4543902

SCHEMBL4543902

SCHEMBL4543902

COC(=O)CS(=O)(=O)N(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 4/20 0.42
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ CA12 O43570 6/20 0.40
▸ CA14 Q9ULX7 5/20 0.40
▸ HSD17B10 Q99714 1/20 0.39
▸ MGAM O43451 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ SI P14410 1/20 0.39
▸ MGAM2 Q2M2H8 1/20 0.39
▸ F2 P00734 1/20 0.35
▸ PRSS1 P07477 1/20 0.35
▸ PRSS2 P07478 1/20 0.35
▸ PRSS3 P35030 1/20 0.35
▸ CA2 P00918 4/20 0.33
▸ CA1 P00915 2/20 0.33
▸ CA9 Q16790 3/20 0.33
▸ CA7 P43166 2/20 0.32
▸ TET2 Q6N021 1/20 0.32
▸ HPGD P15428 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21798314 0.79 MEN1 (0.36) TSHRMEN1KMT2ACA12CA14
SCHEMBL25629543 0.77 TSHR (0.50) TSHRMEN1KMT2ACA12CA14
SCHEMBL22345325 0.77 MEN1 (0.39) TSHRMEN1KMT2ACA12CA14
SCHEMBL7305186 0.74 MEN1 (0.40) TSHRMEN1KMT2ACA12CA14
SCHEMBL10622350 0.74 TSHR (0.52) TSHRMEN1KMT2ACA12CA14
SCHEMBL9867722 0.72 ALDH1A1 (0.33) CA2CA1SMN1; SMN2
SCHEMBL4248401 0.72 POLB (0.48) CA2CA1
SCHEMBL1968530 0.72 — —
SCHEMBL1123070 0.72 — —
SCHEMBL22345276 0.72 TSHR (0.36) TSHRMEN1KMT2ACA12CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12466821-B2 Antiviral pyridopyrazinedione compounds NOVARTIS AG (CH) 2025-11-11 — — US disclosed
US-20230052629-A1 ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2023-02-16 — — US disclosed
US-20230052629-A1 ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2023-02-16 — — US disclosed
US-11072610-B2 Antiviral pyridopyrazinedione compounds NOVARTIS AG (CH) 2021-07-27 — — US disclosed
US-11072610-B2 Antiviral pyridopyrazinedione compounds NOVARTIS AG (CH) 2021-07-27 — — US disclosed
EP-3849979-A1 ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS Novartis AG (CH) 2021-07-21 — — EP disclosed
WO-2020053654-A1 ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS NOVARTIS AG (CH) 2020-03-19 — — WO disclosed
US-20200079772-A1 ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS NOVARTIS AG (CH) 2020-03-12 — — US disclosed
US-10160726-B2 Quinolone derivatives as antibacterials NOVARTIS AG (CH) 2018-12-25 — — US disclosed
US-20170217897-A1 QUINOLONE DERIVATIVES AS ANTIBACTERIALS WUXI APPTEC (CN) 2017-08-03 — — US disclosed
US-8222269-B2 Tyrosine kinase inhibitors MERCK SHARP & DOHME CORP. (US) 2012-07-17 — — US disclosed
US-8101603-B2 Tyrosine kinase inhibitors MERCK SHARP & DOHME CORP. (US) 2012-01-24 — — US disclosed
US-8101603-B2 Tyrosine kinase inhibitors MERCK SHARP & DOHME CORP. (US) 2012-01-24 — — US disclosed
US-20090203684-A1 Tyrosine kinase inhibitors MERCK SHARP & DOHME LLC 2009-08-13 — — US disclosed
US-20090203684-A1 Tyrosine kinase inhibitors MERCK SHARP & DOHME LLC 2009-08-13 — — US disclosed
EP-2049494-A2 TYROSINE KINASE INHIBITORS Merck & Co., Inc. (US) 2009-04-22 — — EP disclosed
US-20090012076-A1 Tyrosine kinase inhibitors MERCK SHARP & DOHME LLC 2009-01-08 — — US disclosed
US-20090012076-A1 Tyrosine kinase inhibitors MERCK SHARP & DOHME LLC 2009-01-08 — — US disclosed
WO-2008008310-A2 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2008-01-17 — — WO disclosed
WO-2008008310-A2 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2008-01-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170217897-A1 QUINOLONE DERIVATIVES AS ANTIBACTERIALS TOP1, NQO2, TOP2A TSHR 4815/4885MEN1 2882/4885KMT2A 3192/4885
US-20090012076-A1 Tyrosine kinase inhibitors ABL1, ERBB2, MET TSHR 1677/4885MEN1 2422/4885KMT2A 414/4885
US-12466821-B2 Antiviral pyridopyrazinedione compounds ZC3HAV1, IL5, TYMP TSHR 4291/4885MEN1 2029/4885KMT2A 2738/4885
US-20090203684-A1 Tyrosine kinase inhibitors ABL1, MET, ERBB2 TSHR 1817/4885MEN1 2512/4885KMT2A 492/4885
US-20230052629-A1 ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS ZC3HAV1, IL5, TYMP TSHR 4291/4885MEN1 2029/4885KMT2A 2738/4885
US-10160726-B2 Quinolone derivatives as antibacterials TOP1, NQO2, TOP2A TSHR 4815/4885MEN1 2882/4885KMT2A 3192/4885
US-11072610-B2 Antiviral pyridopyrazinedione compounds ZC3HAV1, IL5, TYMP TSHR 4291/4885MEN1 2029/4885KMT2A 2738/4885
US-20200079772-A1 ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS ZC3HAV1, IL5, TYMP TSHR 4291/4885MEN1 2029/4885KMT2A 2738/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.